Rossari Biotech Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
No of Months
12
12
12
12
12
12
Profit Before Tax
202.00
185.00
177.00
144.00
136.00
106.00
Adjustment
85.00
84.00
76.00
82.00
55.00
20.00
Changes In working Capital
-153.00
-72.00
-156.00
-27.00
-112.00
-48.00
Cash Flow after changes in Working Capital
133.00
196.00
97.00
199.00
79.00
79.00
Cash Flow from Operating Activities
65.00
137.00
43.00
151.00
29.00
47.00
Cash Flow from Investing Activities
-220.00
-183.00
-103.00
-180.00
-298.00
-37.00
Cash Flow from Financing Activities
186.00
64.00
16.00
60.00
291.00
-24.00
Net Cash Inflow / Outflow
31.00
19.00
-44.00
31.00
22.00
-14.00
Opening Cash & Cash Equivalents
44.00
25.00
69.00
37.00
15.00
29.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
75.00
44.00
25.00
69.00
37.00
15.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Rossari Biotech
Figures in Cr
standaloned Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
191.06
244.66
-53.00
-21.91%
Adjustment
15.01
39.35
-24.00
-61.86%
Changes In working Capital
-95.81
-109.89
14.00
12.81%
Cash Flow after changes in Working Capital
110.26
174.12
-64.00
-36.68%
Cash Flow from Operating Activities
58.73
116.2
-58.00
-49.46%
Cash Flow from Investing Activities
-102.12
-17.94
-85.00
-469.23%
Cash Flow from Financing Activities
79.13
-28.45
107.00
378.14%
Net Cash Inflow / Outflow
35.74
69.81
-34.00
-48.80%
Opening Cash & Cash Equivalents
12.91
6.96
6.00
85.49%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
48.65
76.78
-28.00
-36.64%
Cash Flow - Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -52.66% vs 217.71% in Mar 2025
Mar'26
Mar'25
Change(%)
Cash Flow from Operating Activities
65.07
137.44
-52.66%






